Gemcitabine plus docetaxel as first-line biweekly therapy in locally advanced and/or metastatic urothelial carcinoma: A phase II study

Anti-Cancer Drugs

Volumn 18, Issue 10, 2007, Pages 1207-1211

  Neri, Bruno ^a   Vannini, Laura ^b   Giordano, Clara ^a   Grifoni, Raffaella ^a   Pantaleo, Pietro ^b   Baldazzi, Valentina ^a   Crisci, Alfonso ^a   Lapini, Alberto ^a   Raugei, Andrea ^a   Carini, Marco ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Azienda Ospedaliero Universitaria ^*

Author keywords

Chemotherapy; Docetaxel; Gemcitabine; Urothelial carcinoma

Indexed keywords

DOCETAXEL; GEMCITABINE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; LUNG TOXICITY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; UROGENITAL TRACT TUMOR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; TAXOIDS; TREATMENT OUTCOME; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 34748837817     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3282be8d5a     Document Type: Article

References (25)

1. Ferlay J, Bray F, Pisani P, Parkin DM. Cancer incidence, mortality and prevalence wordwide. Lyon: IARC Press; 2001.
2. Von der Maase H. Current and future prospectives in advanced bladder cancer: is there a new standard?. Semin Oncol 2002; 29:3-14.
3. Vaughn DJ. Review and outlook for the role of paclitaxel in urothelial carcinoma. Semin Oncol 1999; 26:117-122.
4. Sternberg CN, Yagoda A, Scher HI, Waston RC, Geller N, Herr HW, et al. Methotrexate, vinblastine doxorubicin and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 1989; 64:2448-2458.
5. Loeher PJ, Einhorn LH, Elson PJ, Crawford Ed, Kubler P, Tannok I, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992; 10:1066-1073.
6. Saxman SB, Propert KJ, Einnhorn LH, Crawford ED, Tannock I, Raghavan D, et al. Long-term follow-up of a phase III Intergroup study of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997; 15:2564-2569.
7. Von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin vs. methotrexate, vinblastine doxorubicin, and cisplatin in advanced or metastatic bladder cancer: result of a large randomized, multinational multicenter phase II study. J Clin Oncol 2000; 18:3068-3077.
8. Galsky MD. The role of taxanes in the management of bladder cancer. Oncologist 2005; 10:792-798.
9. Pectasides D, Visvikis A, Aspropotamitis A, Halikia A, Karvounis N, Dimitriadis M, Athanassiou A. Chemotherapy with cisplatin, epirubicin, and docetaxel in transitional cell urothelial cancer. Phase II trial. Eur J Cancer 2000; 36:74-79.
10. Gitlitz BJ, Baker C, Chapman Y, Allen HJ, Bosserman LD, Patel R, et al. A phase II study of gemcitabine and docetaxel in patients with advanced urothelial carcinoma. Cancer 2003; 98:1863-1869.
11. Hainsworth JD, Meluch AA, Litchy S, Schnell FM, Bearden JD, Yost K, Greco FA. Paclitaxel, carboplatin and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium. Cancer 2005; 103:2298-2303.
12. Miller AB, Hoogstraten B, Staquet M, Wikler A. Reporting results of cancer treatment. Cancer 1981; 72:207-214.
13. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10:1-10.
14. Kaplan E, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 1958; 53:457-481.
15. Lentner C. Exact Confidence Limits. In Geigy Scientific Tables 89-102. Ciba-Geigy, Switzerland, 1982.
16. Roth BJ, Einhorn LH. Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 1994; 12:2264-2270.
17. McCafferyb JA, Hilton S, Mazumdar M. Phase II trial of docetaxel in patients with advanced or metastatic transitional cell carcinoma. J Clin Oncol 1997; 15:589-593.
18. Rothenberg ML, Sharma A, Weiss GR, Villalona-Calero MA, Eckardt JR, Aylesworth C. Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors. Ann Oncol 1998; 19:733-738.
19. Stemberg CN, Calabrò F, Pizzocaro G, Marini L, Schnetzer S, Sella A. Chemotherapy with an every 2 weeks regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 2001; 92:2993-2998.
20. Sherman WH, Fine RL. Combination gemcitabine and docetaxel therapy in advanced adenocarcinoma of the pancreas. Oncology 2001; 60:313-321.
21. Alexopuolos A, Tryfonopoulos D, Karamouzis MV, Gerasimidis G, Karydas I, Kandilis K, et al. Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer. Ann Oncol 2004; 15:95-99.
22. Roychowdhury DF, Cassidy CA, Peterson P. A report on serious pulmonary toxicity associated with gemcitabine-based therapy. Invest New Drugs 2002; 20:311-315.
23. Shord SS, Faucette SR, Gillenwater HH. Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2003; 51:328-336.
24. Li J, Juliar B, Yiannoutsos C, Ansari A, Fox E, Fisch MJ, et al. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier oncology group study. J Clin Oncol 2005; 23:1185-1191.
25. Ardavanis A, Tryfonopuolos D, Alexopoulos A, Kandylis A, Lainakis G, Rigatos G. Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study. Br J Cancer 2005; 92:645-650.